Anixa obtains cancer vaccine targeted to proteins common in breast cancer from Cleveland Clinic. Arxx licenses Cancer Research UK antibody that targets tumor microenvironment.

Juvaris BioTherapeutics Inc.'s technology is an offshoot of gene therapy work originally conducted at Valentis. Researchers there discovered that their DNA/lipid delivery combination elicited a mild immune response at the lowest dose. Juvaris has used the technology to develop two classes of products: JuvImmune is made up of the DNA/lipid combination without an antigen and is intended to boost the immune response. Combined with vaccines, where it boosts the intensity of the immune response, the technology is called JuvaVax.

Founded in close affiliation with Denver's AMC Cancer Research Center, Oncology Sciences Corp. is taking a natural approach to fighting prostate cancer. It is focusing on preclinical development of an endogenous angiogenesis inhibitor as well as other natural substances that work through anti-angiogenic and additional mechanisms.

THM Biomedical Inc. has been quietly fabricating bioresorbable architectures useful in tissue engineering for years. The company begins with a well-known biocompatible material, an amorphous form of polylactic acid, and it creates open-celled three-dimensional architectures that suit a wide range of applications in tissue repair and reconstruction.